European Association of Nuclear Medicine: At an advanced stage prostate cancer frequently leads to bone metastases which may result in pain, fractures, and disability and are associated with a poor prognosis. Recently a major breakthrough has been achieved which is about to improve the patients’ situation, as Prof. Markus Luster, expert of the European Association of Nuclear Medicine (EANM), points out: “Radium-223- dichloride is the first bone-targeted drug that not only alleviates symptoms but also prolongs the life expectancy of these patients.
Latest from John Shanahan
- Energy Security and Sovereignty (Rob Jeffrey) South Africa
- Need to wear old clothes, forgo heat, air conditioning, travel (CBS) world
- Global Warming for the Two Cultures (Richard Lindzen, GWPF) USofA UK
- Is a Little Radiation Good For You? (Mohan Doss, Discover Magazine, Nathaniel Scharping) USofA
- The incredible growth of the middle class (Homri Kharas, Free Market Foundation, James Peron, Leon Louw) South Africa, USofA world